- Home
- ZNTL
as 07-26-2024 4:00pm EST
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 300.4M | IPO Year: | 2020 |
| Target Price: | $13.14 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.27 - $29.03 | Next Earning Date: | 08-07-2024 |
| Revenue: | $40,560,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -92.66% |
Stock Insider Trading Activity of Zentalis Pharmaceuticals Inc. (ZNTL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gallagher Cam | ZNTL | President, Interim CFO | May 31 '24 | Sell | $11.98 | 9,597 | $114,972.06 | 633,680 | SEC Form 4 |
| HAUSMAN DIANA | ZNTL | Chief Medical Officer | May 9 '24 | Sell | $12.62 | 3,356 | $42,352.72 | 373,876 | SEC Form 4 |
| Epperly Melissa B, | ZNTL | Chief Financial Officer | Feb 12 '24 | Sell | $11.44 | 2,573 | $29,435.12 | 451,449 | SEC Form 4 |
| Gallagher Cam | ZNTL | President | Feb 12 '24 | Sell | $11.44 | 1,173 | $13,419.12 | 643,277 | SEC Form 4 |
| Lackner Mark | ZNTL | Chief Scientific Officer | Feb 1 '24 | Sell | $11.54 | 1,585 | $18,290.90 | 195,728 | SEC Form 4 |
| Paul Andrea | ZNTL | Chief Legal Officer | Feb 1 '24 | Sell | $11.54 | 3,310 | $38,197.40 | 149,973 | SEC Form 4 |
| Epperly Melissa B, | ZNTL | Chief Financial Officer | Feb 1 '24 | Sell | $11.54 | 8,669 | $100,040.26 | 454,022 | SEC Form 4 |
| Gallagher Cam | ZNTL | President | Feb 1 '24 | Sell | $11.54 | 11,552 | $133,310.08 | 644,450 | SEC Form 4 |
| Johnson David Michael | ZNTL | Director | Nov 10 '23 | Buy | $9.88 | 17,000 | $167,943.00 | 144,389 | SEC Form 4 |
Latest Zentalis Pharmaceuticals Inc. News
ZNTL Breaking Stock News: Dive into ZNTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
MT Newswires
a month ago
UBS Downgrades Zentalis Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $28
Zacks
a month ago
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
Clinical Trials Arena
a month ago
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
MT Newswires
a month ago
US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth
MT Newswires
a month ago
Top Midday Decliners
MT Newswires
a month ago
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $10 From $32, Maintains Buy Rating
Compare ZNTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZNTL Zentalis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.